Head-To-Head Analysis: MiMedx Group (NASDAQ:MDXG) and Stevanato Group (NYSE:STVN)

MiMedx Group (NASDAQ:MDXG) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Volatility and Risk

MiMedx Group has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

Valuation and Earnings

This table compares MiMedx Group and Stevanato Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$348.88 million	3.35	$58.23 million	$0.28	28.29
Stevanato Group	$1.10 billion	5.45	$157.62 million	€0.48 ($0.52)	41.42

Stevanato Group has higher revenue and earnings than MiMedx Group. MiMedx Group is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for MiMedx Group and Stevanato Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	0	0	3	0	3.00
Stevanato Group	0	2	6	0	2.75

MiMedx Group presently has a consensus target price of $12.00, suggesting a potential upside of 51.52%. Given MiMedx Group’s stronger consensus rating and higher possible upside, equities research analysts clearly believe MiMedx Group is more favorable than Stevanato Group.

Insider and Institutional Ownership

79.2% of MiMedx Group shares are owned by institutional investors. 1.3% of MiMedx Group shares are owned by company insiders. Comparatively, 0.7% of Stevanato Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares MiMedx Group and Stevanato Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiMedx Group	23.86%	26.21%	18.15%
Stevanato Group	10.47%	9.86%	5.79%

Summary

MiMedx Group beats Stevanato Group on 8 of the 14 factors compared between the two stocks.

About MiMedx Group

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.